Werewolf Therapeutics (NASDAQ:HOWL) Releases Quarterly Earnings Results, Misses Estimates By $0.03 EPS

Werewolf Therapeutics (NASDAQ:HOWL) posted its quarterly earnings data on Tuesday. The company reported ($0.46) EPS for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.03), Zacks reports. Werewolf Therapeutics had a negative return on equity of 58.83% and a negative net margin of 578.80%.

Werewolf Therapeutics Price Performance

HOWL opened at $1.23 on Tuesday. The firm has a market cap of $54.59 million, a P/E ratio of -0.80 and a beta of 0.37. The firm has a 50-day moving average of $1.38 and a 200 day moving average of $1.83. The company has a debt-to-equity ratio of 0.29, a quick ratio of 10.10 and a current ratio of 10.10. Werewolf Therapeutics has a fifty-two week low of $1.03 and a fifty-two week high of $6.89.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on HOWL shares. JMP Securities lowered their price objective on shares of Werewolf Therapeutics from $12.00 to $4.00 and set a “market outperform” rating for the company in a research report on Tuesday, January 14th. HC Wainwright reiterated a “buy” rating and issued a $15.00 target price on shares of Werewolf Therapeutics in a report on Tuesday, November 19th.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.